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Abstract
In the nineteenth century, smallpox ravaged through the United States and Canada. At this time, a botanical preparation,
derived from the carnivorous plant Sarracenia purpurea, was proclaimed as being a successful therapy for smallpox
infections. The work described characterizes the antipoxvirus activity associated with this botanical extract against vaccinia
virus, monkeypox virus and variola virus, the causative agent of smallpox. Our work demonstrates the in vitro
characterization of Sarracenia purpurea as the first effective inhibitor of poxvirus replication at the level of early viral
transcription. With the renewed threat of poxvirus-related infections, our results indicate Sarracenia purpurea may act as
another defensive measure against Orthopoxvirus infections.
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Introduction
I nt h el a t e1 8 0 0 ’ s ,t h eM i c m a cI n d i a n so fN o v aS c o t i a
proclaimed the existence of a botanical-based remedy for
smallpox. During this time, Herbert Miles, the Assistant
Surgeon to the Royal Artiller y ,r e p o r t e dt h a td u r i n ga n
outbreak of smallpox ‘‘an old squaw going amongst them, and
treating the cases with (a botanical) infusion…was so successful
as to cure every case’’. This botanical infusion was later
described as being derived from the carnivorous plant, Sarracenia
purpurea [1,2].
In 1892, Charles Millspaugh described that the Native
Americans of eastern North America used S. purpurea as a poultice
against smallpox and it provided ‘‘the greatest remedy known for
the dreadful scourge’’ [3]. C.G. Logie, Surgeon-Major of the
Royal Horse Guards, treated variola-infected men in his regiment
and found that S. purpurea ‘‘seemed to arrest the development of
the pustules, killing, as it were, the virus from within, thereby
changing the character of the disease and doing away with the
cause of pitting’’ [4]. However, the putative medicinal properties
of S. purpurea have been largely forgotten.
Before human development, S. purpurea, also known as Hunts-
man’s Cup, Side-saddle flower or Indian Pitcher Plant, was widely
distributed ranging from Labrador to Florida along the Atlantic
seacoast of North America and westward to Wisconsin and
Minnesota [13,14]. S. purpurea is an insectivorous bog plant, the
leaves of which form cups and become filled with water to capture
insects.
Smallpox outbreaks have occurred within the human popula-
tion for thousands of years, but the natural disease is now
considered eradicated after a successful worldwide vaccination
program. In recent years there has been a heightened concern that
variola virus might be used as an agent of bioterrorism [30]. In
addition, the related monkeypox virus represents an emerging
threat to the human population [19,30]. Though the vaccine
provides effective protection against poxvirus infection, side effects
and risks associated with the smallpox vaccine are reasonably
common and can be quite severe [27,30]. The increasing threat of
Orthopoxvirus-related infections highlights the need to discover
effective poxvirus countermeasures. In this manuscript we present
the ‘rediscovery’ and characterization of S. purpurea as an effective
inhibitor of Orthopoxvirus replication.
Methods
Cell lines and viruses
Rabbit Kidney (RK-13, American Type Culture Collection
(ATCC) CCL-37) cells were maintained in Eagle’s Minimal
Essential Medium (MEM) (Cellgro) supplemented with 5% fetal
bovine serum (FBS) (HyClone). HeLa (ATCC CCL-2) were
maintained in Dulbecco’s Modified-Minimal Essential Medium
(DMEM) (Cellgro) supplemented with 5% FBS. All cells were
incubated at 37uC in the presence of 10% CO2. Vaccinia virus
(Copenhagen strain), designated as VACV, was provided by
Virogenetics. Monkeypox virus (Walter Reed 267 strain),
designated as MPXV, was provided by BEI Resources. Variola
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used for experiments at the Centers for Disease Control and
Prevention (Atlanta, GA). Adenovirus Type 5 (Adeno), vesicular
stomatitis virus, Indiana strain (VSV), mouse hepatitis virus A59
(MHV), reovirus Type 3, Dearing strain (Reo), encephalomyo-
carditis virus (EMCV) were obtained from American Type
Culture Collection (ATCC). For MHV, HeLa-MHVR cells
expressing the MHV A59 CEACAM (carcinoembryonic antigen
cell adhesion molecule isoform 1a) receptor were kindly provided
by Tom Gallagher (Loyala University Medical Center, Maywood,
IL).
Botanical extract preparation
The following herbs were used in this study: Sarracenia purpurea,
Astragalus membranaceus, Echinacea angustifolia, and Coriolus versicolor.
For the preparation of S. purpurea extract, fresh whole plants grown
in a greenhouse in the Southeastern United States were shipped
overnight express and received at the manufacturing facility
(Sedona, AZ). The plants were manually cleaned on the same day,
with special attention to cleaning the base portion of the plant’s
pitcher structure so that it was free from contamination with forest
detritus. Cleaned whole plant was ground gently in a Hamilton
Beach Stainless steel blender in the presence of a blend of 190-
proof grain ethanol/distilled water/vegetable glycerin (63%/
32%/5%). The plant/liquid mixture was transferred to an amber
colored glass container, sealed tightly, and incubated at room
temperature for 48 days. The liquid was pressed from the solid
plant material, filtered through unbleached paper filters, pooled,
and bottled in amber colored glass bottles. Fresh Echinacea
angustifolia roots were harvested from central Kansas. All fresh
plants were shipped overnight express to the manufacturing facility
for immediate validation and processing. Fresh plant material was
validated using taxonomic keys. Dried Astragalus membranaceus root
slices were purchased from Mayway Corporation (Oakland, CA).
Dried plant material was validated using herbal pharmacopoeia
monographs. Fresh plants were mixed with distilled water/190
proof ethanol/glycerol at a ratio 1:3 (Echinacea) [weight of
botanical to volume of liquid], ground gently in a 1 gallon
stainless steel Hamilton Beach blender, and the herb-liquid
mixture was transferred to a clean amber colored gallon glass jar
and sealed. Dried botanicals were ground in a 1 gallon stainless
steel Hamilton Beach blender, transferred to a clean amber
colored gallon glass jar, and a mixture of distilled water/190 proof
ethanol/glycerol was added at a ratio of 1:5 (weight of botanical to
volume of liquid). Distilled water/190 proof ethanol/glycerol
concentrations were as followed (Astragalus 74/26/0; Echinacea 48/
47/5). The mixtures were kept at room temperature for 2 to 6
weeks, followed by separation of the liquid portion from the solid
herb portion using a mechanical press. The extracted liquid was
filtered using unbleached paper filters, pooled, and dispensed in
amber colored bottles. A sample of each extract was dried and all
extracts were found to contain similar concentrations of non-
volatile solutes (ranging between 62.4–136.8 mg/ml extract).
Cidofovir treatment
Cidofovir (Sigma-Aldrich) treatment was done as previously
described [15,16].
VACV plaque assay
RK-13 cells were infected with 150 pfu of VACV. At 15 mpi,
the virus was removed and 0, 1, 3, 10, and 30 microL of S. purpurea
extract per mL of cell culture media was added. For the cells
receiving multiple S. purpurea treatments, media was replaced with
fresh media containing the varying amounts of S. purpurea extract
every six hours. Cells were incubated at 37uC in the presence of
5% CO2 for 48 hours. VACV plaques were visualized by crystal
violet staining [23].
Single-cycle growth kinetics
RK-13 cells were infected with VACV at an MOI of 10 for
15 min, washed 2 times with media, and treated with 25 microL S.
purpurea extract/mL media. For the cells receiving multiple S.
purpurea treatments, media was replaced with fresh media
containing the varying amounts of S. purpurea extract every six
hours. Cells not treated with S. purpurea, were treated with 25
microL 63% ethanol, 5% glycerol solution (ethanol/glycerol
carrier)/mL media. Infected cells were harvested at 2, 6, 12, 18
and 24 hpi by scraping into the media and freeze/thawing 3 times.
Viral titers were determined by plaque assay and crystal violet
staining in RK-13 cells.
Orthopoxvirus protein synthesis and CPE
HeLa cells were infected with VACV at an MOI=10 for
15 minutes, washed 26with media and treated with 25 microL S.
purpurea extract/mL media at 0, 15, 30, 60, and 120 mpi. Cell
monolayers were photographed at 6 hpi to record VACV-induced
CPE. At 3 and 6 hpi cell lysates were prepared by RIPA lysis [24].
Cell lysates were analyzed on 12% polyacrylamide gels by SDS-
PAGE. Proteins were transferred nitrocellulose membranes,
incubated with antibodies directed against the VACV-E3L protein
or against total VACV proteins, and detected by chemilumines-
cence (Pierce SuperSignal West Pico Chemiluminescence Sub-
strate). The relative levels of E3L protein were quantified using
ImageQuant software. MPXV infections were done under the
same conditions using a BSL-3 facility and treating with S. purpurea
at 0 and 15 mpi. VARV infections were done at the Centers for
Disease Control and Prevention (Atlanta, GA) under similar
conditions using a BSL-4 facility and treating with S. purpurea at 0
mpi. Infections with Adeno, VSV, MHV, and Reo viruses were
done similarly with S. purpurea treatment at 15 mpi and lysates
prepared at 8 hpi. Antibodies specific for the Adeno-E1, VSV-G,
MHV-E and Reo-core proteins were used to measure viral protein
synthesis. Treatment of VACV with other botanical extracts
(Echinacea, Astragalus, Coriolus, and Glycyrrhiza) were done at 15 mpi
at 25 microL extract/mL media and cell lysates prepared at 6 hpi.
Cell viability
HeLa cells were treated with S. purpurea at the concentrations
indicated. Viability was determined by trypan blue exclusion at
6 hours post treatment.
Immunofluorescence
Subconfluent HeLa cells, grown on poly-l-lysine coated
coverslips, were infected with a VACV construct in which the
cyan fluorescent protein was fused to the core A5 protein (kindly
provided by B. Moss, NIH) at an MOI=20. The infection was
kept at 4uC or room temperature for 10 minutes, washed 2-times
with media, and treated with S. purpurea extract. After 1 hour of
treatment, cells were rinsed with PBS and fixed with 4%
paraformaldehyde for 20 minutes at room temperature. The cells
were quenched with 50 mM ammonium acetate in PBS for
10 minutes at room temperature. The cells were rinsed with PBS
and permeabilized with 0.2% Triton X-100 for 15 minutes at
room temperature. The cells were blocked with blocking buffer
GTP (0.2% gelatin/0.1% Triton X-100/1XPBS) for 30 minutes
followed by overnight staining with eIF2-alpha antiserum (Cell
Signaling) at 1:500 dilution at 4uC. Secondary antibodies (Alexa
Botanical Therapy for Smallpox
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GTP for 1 hour at room temperature followed by 3 washes of
GTP. The coverslips were mounted in ProLong Gold antifade
reagent (Invitrogen) and samples analyzed using Zeiss Duo
confocal microscope.
VACV in vivo protein labeling
HeLa cells were infected by VACV at an MOI of 10 for
15 minutes, washed 26with media, and treated with 25 microL S.
purpurea extract/mL media. Cells not treated with S. purpurea, were
treated with 25 microL 63% ethanol, 5% glycerol solution
(ethanol/glycerol carrier)/mL media. Cells were labeled with
[
35S]-methionine/cysteine Protein Label Mix (Perkin-Elmer) at 4
hpi, as previously described [25]. Cell lysates were analyzed on
12% polyacrylamide gels by SDS-PAGE, dried down on
Whatmann filter paper and analyzed by autoradiography.
Real-time PCR
HeLa cells were mock infected or infected with VACV at an
MOI of 10 for 15 min, washed 26with media, and treated with
25 microL S. purpurea extract/mL media. At 4 hpi, total RNA was
isolated by the Qiagen RNeasy Mini kit according to the
manufacture’s protocol. Early RNA levels were quantitatively
determined by real-time PCR using specific primers for VACV-
E3L mRNA. RNA concentrations were all equalized and real-time
PCR was performed with 1 or 10 microL of total RNA.
Viral core in vitro transcription
VACV virion cores were isolated as previously described [26].
Cores were incubated with the indicated amounts of S. purpurea or
ethanol/glycerol carrier. In vitro transcription assays were per-
formed as previously described in the presence of [
35S]-UTP [26].
A no template reaction was performed by excluding the virion
cores. All reactions were done in the presence of Superase-In
RNase inhibitor (Ambion). Completed transcription reactions
were spotted onto glass-fiber filters, washed 3-times in 10% TCA,
and radioactivity was measured by scintillation counting.
Results
Sarracenia prevented VACV replication
Initial analysis was done to measure the ability of S. purpurea
extract to inhibit poxvirus infections in vitro. We examined the
ability of S. purpurea to prevent vaccinia virus (VACV) plaque
formation in cells treated immediately after infection with
increasing amounts of extract, administered once or every six
hours, for a total of 24 hours. We observed a dose dependent
reduction in VACV plaquing efficiency associated with increasing
amounts of S. purpurea extract (Fig. 1a). To ensure S. purpurea was
responsible for the decrease in plaquing efficiency, cells were
treated with 63%:32%:5% ethanol:distilled water:glycerol (carrier
for the S. purpurea extract) prior to infection. This carrier treatment
did not affect VACV plaquing efficiency (data not shown).
Next we assayed for the ability of VACV to replicate in cells
under single-cycle conditions, treated once or every six hours, with
S. purpurea extract. Treatment with S. purpurea began immediately
following VACV infection and viral titers were determined every
six hours. S. purpurea treatment resulted in a dramatic decrease in
VACV replication, when compared to the untreated cells (Fig. 1b).
A single treatment of S. purpurea, caused a 100–1000 fold reduction
in VACV replication throughout the course of the infection,
however some viral replication was still observed. In cells treated
with fresh extract every six hours, a 10,000-fold decrease in VACV
replication was observed. Multiple treatments with S. purpurea
completely abolished VACV replication since titers did not
increase over the course of the infection. In cells treated with
the carrier, VACV replicated to levels similar to that seen in
untreated cells (data not shown). To further determine the efficacy
of using S. purpurea to treat a poxvirus infection, we determined the
selectivity index (SI) associated with the extract. In S. purpurea
treated cells, the dose required to inhibit VACV replication 50%
(EC50) was 10–15 microL/mL, while the dose which induced 50%
cytotoxicity (CC50) was 70–75 microL/mL, resulting in a SI of
approximately 5–7 (Fig. 1c). Previous studies have demonstrated
that cidofovir (CDV), an already proven treatment for poxvirus
infections, has an SI of 6–6.2 in HFF cells [15–18]. To compare
our results to those of cidofovir, VACV-infected HeLa cells were
treated with cidofovir and viral inhibition and cellular toxicity
measured (Fig. 1d). Our results demonstrated an EC50 for
cidofovir of approximately 30 microg/ml, however in cidofovir-
treated HeLa cells, no significant toxicity was observed at
concentrations up to 640 microg/ml (shown to a dose of
320 microg/ml). This lack of cellular toxicity was similar to that
reported previously for cidofovir treated BSC-40 cells [33].
To further compare viral inhibitory activity of the S. purpurea
extract to cidofovir, the inhibition of viral-induced cytopathic
effect (CPE) was evaluated. As shown in Fig. 1e, VACV infection
led to significant CPE by 4 HPI (compare Mock to VACV). In a
similar infection treated with S. purpurea, viral CPE was completed
inhibited (Fig. 1e). When the infection was treated with cidofovir,
CPE was still observed (Fig. 1e).
Sarracenia inhibited replication early
The results in Fig. 1e suggest that cidofovir and S. purpurea are
acting on different targets in the VACV replication cycle and that
S. purpurea may be inhibiting virus replication early in the
replication cycle prior to the induction of CPE. In order to
understand the mechanism of antiviral activity associated with S.
purpurea, various treatment schedules were tested. In cells treated
with a single dose of S. purpurea overnight prior to infection with
VACV followed by washing, no inhibition of VACV replication
was observed, suggesting the extract does not induce a cellular
antiviral component (data not shown). Moreover, treating a
purified VACV stock with S. purpurea did not affect replication of
the virus, indicating that the extract does not have a direct affect
on free virus particles (data not shown). To determine when S.
purpurea treatment was most effective at preventing VACV
replication, we examined the ability of S. purpurea to prevent
VACV induced CPE when added at various times post-infection.
In this assay, cells were infected with VACV and then treated with
S. purpurea at the indicated times post-infection. At 6 hpi, the cells
were examined for VACV induced CPE. In untreated cells,
significant VACV induced CPE, specifically cell rounding, was
observed (Fig. 2a). However, cells treated at 0, 15, and 30 minutes
post-infection (mpi) with S. purpurea showed no or low levels of
CPE. In cells treated at 60 and 120 mpi, substantial CPE was
observed These results are in agreement with Fig. 1e that S.
purpurea was likely targeting an early component in VACV
replication (ie. viral uptake or early viral transcription/translation).
Using a VACV construct in which the core A5 protein was
fused to cyan fluorescent protein, we were able to monitor viral
uptake into the cell. As shown in Fig. 2b, when the VACV
infection was done at 4uC, virus particles remained localized to the
periphery of the cell. When the infection was done at 37uC, the
majority of virus particles were observed within the cytoplasm.
When a similar infection at 37uC was done in the presence of S.
purpurea, a similar viral localization to the cytoplasm was observed
Botanical Therapy for Smallpox
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VACV uptake into the cell.
We examined if early viral protein synthesis was inhibited
following S. purpurea treatment. VACV-infected cells were treated
with S. purpurea at various times post infection and cell lysates were
assayed by Western blot using antibodies directed against total
VACV proteins or the early VACV protein, E3L. VACV protein
synthesis at 3 and 6 hpi in the cells treated at 0, 15, and 30 minutes
post infection with S. purpurea, was greatly reduced (Fig. 2c).
Notably, S. purpurea reduced early VACV protein synthesis, as
evidenced by the absence of the VACV-E3L protein. In contrast,
S. purpurea treatment had only marginal affects on viral protein
levels when added at 60 and 120 minutes post infection. Cells
were also [
35S]-methionine metabolically labelled to compare viral
protein synthesis to cellular protein synthesis following S. purpurea
treatment. As predicted based on the cellular toxicity data (Fig. 1c),
S. purpurea inhibited viral protein synthesis, whereas cellular protein
synthesis remained unaffected (Fig. 2d). Collectively, these data
indicate S. purpurea treatment was effective at preventing VACV
early protein accumulation and acted at a point between viral
uptake and early viral protein synthesis.
Sarracenia inhibited VACV transcription
To further understand the early viral stage affected following S.
purpurea treatment, we quantified early VACV-E3L mRNA levels
in VACV-infected cells using real-time PCR. Total RNA was
isolated from cells that were mock-infected, VACV-infected or
VACV-infected followed by treatment with a single dose of S.
purpurea extract. S. purpurea treatment resulted in a dramatic
reduction of the levels VACV-E3L mRNA present within the
Figure 1. The effect of S. purpurea extracts on VACV replication. A) RK-13 cells were infected with 150 pfu of VACV followed by the addition
of the indicated concentration of S. purpurea extract to the cell culture media. Cells were treated one-time only with the extract (black bars) or every
6 hours with fresh extract (gray bars). After 48 hours, plaques were visualized and quantified. Error bars represent standard deviation (n=3). B) RK-13
cells were infected with VACV at an multiplicity of infection (MOI)=10 followed by addition of ethanol/glycerol carrier (closed diamonds) or the
addition of 25 microL S.purpurea extract/ml media (open squares and closed triangles). Cells were treated one-time only with the extract (open
squares) or every 6 hours with fresh extract (closed diamonds). Cells were harvested at the indicated times and viral titers determined. Error bars
represent deviation between assays (n=2). C) For viral translation levels (closed squares), HeLa cells were infected with VACV at an MOI=10 followed
by the addition of the indicated concentrations of S. purpurea extract/ml media. At 6 HPI, cell lysates were prepared, the VACV E3L protein detected
by Western blot, and quantified. For cell viability, HeLa cells were treated with the indicated concentrations of S. purpurea extract (closed diamonds)
or ethanol/glycerol carrier (closed triangles) for 6 hours and the number of viable cells determined by a trypan blue exclusion assay. D) For viral
plaque formation (closed squares), HeLa cells were infected with VACV (approx. 200 pfu) followed by the addition of the indicated concentrations of
cidofovir to the media. After 48 hours, plaques were visualized and quantified. Error bars represent standard deviation (n=3). For cell viability, HeLa
cells were treated with the indicated concentrations of cidofovir (closed diamonds) for 48 hours and the number of viable cells determined by a
trypan blue exclusion assay. E) HeLa cells were mock-infected or infected with VACV at an MOI=10 followed by the immediate addition of media,
25 microL S. purpurea extract/ml media, or 320 microg cidofovir/ml media. At 4 HPI, the cell monolayers were photographed.
doi:10.1371/journal.pone.0032610.g001
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levels of early VACV mRNA were decreased by 393–474-fold
within the treated cells.
To determine if VACV replication was being blocked at the
level of early viral transcription, we performed an in vitro
transcription assay using purified VACV virion cores and [
3S]-
UTP. The amount of VACV transcription which occurred
following treatment with increasing amounts of S. purpurea or
carrier was measured by quantifying the amount [
3S]-UTP
incorporated into the newly synthesized viral mRNA. As shown,
VACV transcription decreased as the amount of S. purpurea
increased, while the levels of transcription remained relatively
equal in the carrier treated cores (Fig. 3b). The amount of S.
purpurea required to completely inhibit transcription was similar to
the dose that prevented VACV replication (Fig. 1b). Addition of S.
purpurea to VACV cores which had already synthesized RNA did
not reduce RNA levels suggesting that the extract did not have
intrinsic RNase activity (data not shown).
Sarracenia antiviral activity
To further understand the antipoxvirus activity associated with
S. purpurea, we decided to analyze the capability of S. purpurea to
prevent the replication of more virulent members of the
Orthopoxvirus genus, namely monkeypox virus (MPXV) and variola
virus (VARV). Cells were mock-infected or infected with MPXV
and subsequently left untreated or treated with S. purpurea or
carrier at the times indicated. Western blots for the presence of the
MPXV-F3L protein (ortholog of the VACV-E3L protein) were
performed to determine if a successful MPXV infection had
occurred. When treated with the extract at 0 or 15 minutes post
infection, S. purpurea treatment prevented the accumulation of the
MPXV-F3L protein, whereas high levels of MPXV-F3L were
detected in the both the untreated and carrier treated cells (Fig. 4a).
A similar assay was performed with VARV where cells were mock-
infected or infected with VARV and treated with S. purpurea or
carrier at the dosages indicated (Fig. 4b). Western blots for the
presence of the VARV E3L protein indicated a concentration
dependent inhibition in the accumulation of the VARV-E3L
protein in S. purpurea treated infections. In addition, we also
determined that S. purpurea treatment effectively inhibited
rabbitpox virus early protein accumulation (data not shown).
To determine if S. purpurea treatment was effective against other
viruses outside the Poxviridae family, we analyzed the ability of S.
purpurea to block the replication of four unrelated viruses, including
Figure 2. The effect of S. purpurea extracts on VACV induced CPE and protein synthesis. A and C) HeLa cells were infected with VACV at an
MOI=10 followed by the addition of 25 microL S. purpurea extract/ml media immediately (0 min) or at 15, 30, 60 or 120 min post infection. ‘No
treatment’ cells received ethanol/glycerol carrier only. For (A), at 6 HPI, the cell monolayers were photographed. For (C), at 3 HPI, cell lysates were
prepared and the VACV E3L protein or total VACV proteins detected by Western blot. * indicate the position of VACV proteins and the VACV-E3L
protein. Duplicate experiments were done at 6 HPI (not shown) B) Hela cells were infected with a VACV construct expressing cyan fluorescent protein
fused to the viral A5 core protein. In the first panel, the infection was maintained at 4uC. For the middle and last panel, the infection was done at 37uC,
in the absence or presence of S. purpurea, respectively. D) HeLa cells were mock infected or infected with VACV at an MOI=10 followed by the
addition of 25 microL S. purpurea extract/ml media or ethanol/glycerol carrier. At 4 HPI, the cell monolayers were radiolabelled with [
35S]-methionine,
cell lysates prepared, proteins separated by SDS-PAGE, and visualized by autoradiography. * indicate the position of VACV proteins.
doi:10.1371/journal.pone.0032610.g002
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stomatitis virus (VSV) (Rhabdoviridae, (-) sense RNA genome),
mouse hepatitis virus (MHV) (Coronaviridae, (+) sense RNA
genome) and reovirus (Reo) (Reoviridae, dsRNA genome). No
significant decrease in viral protein synthesis for any of the four
viruses tested was detected following treatment with S. purpurea
(Fig. 4c). We also determined that S. purpurea did not affect
encephalomyocarditis or VSV plaque formation (data not shown).
Lastly, we wanted to determine if other botanical extracts could
prevent VACV replication. In this assay, we chose to examine the
effect Echinacea, Astragalus, Coriolus, and Glycyrrhiza botanical
extracts on VACV protein synthesis and plaque formation. These
botanical extracts are thought to be efficacious in the treatment of
other microbial infections [28]. Infected cells were treated with
each extract and assayed for levels of VACV-E3L protein
synthesis. All the botanical extracts contained comparable
amounts of non-volatile components as that of the S. purpurea
extract. As shown, the levels of VACV-E3L decreased dramati-
cally in the S. purpurea treated cells (Fig. 4d). However, the cells
treated with the four other botanical extracts contained levels of
VACV-E3L similar to that seen in the untreated cells. Further-
more, VACV plaquing formation was unaffected by the other
botanical extracts (data not shown).
Discussion
Here we report on the in vitro characterization of antipoxvirus
activity associated with an S. purpurea extract which was
Figure 3. The effect of S. purpurea extracts on VACV transcription in vivo and in vitro. A) HeLa cells were infected with VACV at an MOI=10
followed by the addition of 25 microL S. purpurea extract/ml media. At 4 HPI, total RNA was isolated and VACV-E3L RNA levels determined by real-
time PCR. Reactions contained total RNA from mock-infected cells, ethanol/glycerol carrier-treated VACV-infected cells, or S. purpurea-treated VACV-
infected cells. C(t) values were calculated using manufacturer’s software. Graph illustrates data from a representative experiment. C(t) values and fold
change from two separate experiments are shown. B) Purified VACV virion cores were incubated in the presence of the indicated concentrations of S.
purpurea or ethanol/glycerol carrier and [
35S]-UTP. Newly synthesized RNA products were spotted onto glass-fiber filters, washed in TCA, and
quantified by scintillation counting (counts per minute). A no template reaction was performed by excluding the addition of the virion cores.
doi:10.1371/journal.pone.0032610.g003
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smallpox infection [3,4,6,7,10,12]. During the 1800’s, patients
were treated with S. purpurea after the symptoms for smallpox had
already appeared and as a preventive during epidemics.
Historical reports stated that ‘‘the effects were so…speedy and
beneficial as to leave no doubt that they were due to the
Sarracenia’’ [8]. ‘‘The disease continued very severe until (S.
purpurea) was administered, and became entirely changed in its
severity after the administration…, the effect being due to (S.
purpurea) alone’’ [1]. In this study, we demonstrated that S.
purpurea extracts were able to effectively inhibit viral replication
and the viral-induced cytopathic effects of various Orthopoxviruses.
The data supports that S. purpurea effectively inhibited MPXV
and VARV replication similarly to VACV, and points to the
relevance of using VACV as a model of the more virulent MPXV
and VARV. At doses where virus replication was inhibited, little
to no cellular toxicity was observed.
In regards to broad-spectrum antiviral activity, the data
supports that the antiviral activity associated with S. purpurea was
at least partially specific to poxviruses in comparison to other non-
related viruses tested. Since S. purpurea treated cells were still able
to support the replication of other virus families, it further supports
that S. purpurea treatment does not disrupt the intracellular
environment of the cell. For VACV, a single treatment was fairly
effective at preventing viral replication, but partial replication soon
recovered, likely due to a breakdown or utilization of the active
component(s) within the extract. However, treating the cells with
fresh S. purpurea every six hours completely abolished the
replication of VACV. This correlates well with how patients were
treated in the past where the treatment regime involved taking 4–6
doses of the extract per day [11]. Our data supports that extracts
of S. purpurea effectively inhibit the replication of VACV, MPXV
and VARV in vitro. This activity toward Orthopoxviruses is consistent
with the historical reports of S. purpurea as a therapy against
Figure 4. The specificity of S. purpurea extracts on Orthopoxvirus. A) HeLa cells were mock-infected or infected with monkeypox virus (MPXV)
at an MOI=10 followed by the addition of ethanol/glycerol carrier or 25 microL S. purpurea extract/ml media, either 0 or 15 min after infection. At 4
HPI, cell lysates were prepared and the MPXV F3L protein detected by Western blot. B) HeLa cells were mock-infected or infected with variola virus
(VARV) at an MOI=10 followed by the addition of the indicated concentrations of ethanol/glycerol carrier or S. purpurea extract to the media at 0 min
after infection. At 4 HPI, cell lysates were prepared and the VARV E3L protein detected by Western blot. C) HeLa cells were infected with adenovirus
(Adeno), vesicular stomatitis virus (VSV), mouse hepatitis virus (MHV) or reovirus (reo) followed by the addition of ethanol/glycerol carrier or
25 microL S. purpurea extract/ml media. At 15 min and 8 hours post-infection, cell lysates were prepared and representative viral proteins detected
by Western blot (E1A, G, E, and core proteins, respectively). D) HeLa cells were infected with VACV at an MOI=10 followed by the addition of ethanol/
glycerol carrier (none) or S. purpurea extract, Echinacea extract, Astragalus extract, Coriolus extract, or Glycyrrhiza extract (25 microL/ml media). At 4
HPI, cell lysates were prepared and the VACV E3L protein detected by Western blot.
doi:10.1371/journal.pone.0032610.g004
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poxvirus activity of S. purpurea extracts in order to verify and
evaluate the botanical material under similar preparation methods
as that done historically in the 1800’s. Collectively, the data
suggests that S. purpurea targets early viral transcription leading to
an inhibition in viral replication. In comparison to other
botanicals, the data demonstrate that the anti-poxvirus activity
of the S. purpurea extract was not necessarily shared by other
botanicals. Based on the results presented, future work will involve
fractionation and identification of the active anti-poxvirus
constituent(s) present in the S. purpurea extracts. Cidofovir (CDV)
is a broad spectrum antiviral with activity against several DNA
viruses, including poxviruses. Currently, CDV is the only licensed
parenteral drug with antipoxvirus activity, but its clinical use is
governed by its Investigational New Drug (IND) status [30]. Since
CDV leads to nephrotoxicity and must be administered intrave-
nously, CDV has not been sought as the standardized therapy to
treat poxvirus infections [20]. CMX001, synthesized by coupling
CDV to hexadecyl propanedial alkoxykanol, is currently being
investigated as an alternative to CDV due to increased
bioavailability after oral administration and predicted lack of
nephrotoxicity [31]. Another compound, ST-246 (Tecovirimat),
has been shown to be highly efficacious in the treatment of
poxviruses. ST-246 can be delivered orally and has been reported
to be nontoxic within an animal model [21,32]. To date, ST-246
and CMX001 are the most promising antipoxvirus compounds. A
report issued by the Institute of Medicine, as well as the 2009
WHO Advisory Committee on Variola Virus Research, suggested
that due to the increased susceptibility of the human population to
smallpox, at least two anti-variola virus drugs with different
mechanisms of action should be developed in order to provide
greater protection in the event of a smallpox epidemic [22]. ST-
246 and CMX001 have potent efficiencies and target different
points in the viral replication cycle, but single point mutations in
the poxvirus genome can confer resistance to these drugs.
Therefore, additional anti-poxvirus therapies would certainly aid
in protecting the human population and increase the repertoire of
treatments available.
As a measurement of the efficacy associated with S. purpurea, the
SI was determined to be similar to that previously reported for
CDV [15,16]. Although anecdotal, when extracts of S. purpurea
were used in the late 1800’s, no severe side effects were ever
reported following treatment [1,2,7,8,9,12]. Sarracenia extracts
have a modern use in the southern United States as a laxative for
dyspepsia. In patients ingesting S. purpurea, diuretic responses were
often observed with significantly elevated levels of limpid urine,
but no other physiological effects reported [5]. Further controlled
studies will be necessary to fully understand the safety profile of S.
purpurea. It is possible that S. purpurea may not be as cytotoxic in a
human as compared to a cell-culture system. Indeed, extracts from
the related species, S. flava, have been shown to possess antitumor
activity [29]. It is possible, since the cells used in this study are
established cell lines, the cell toxicity observed may be due to this
antitumorigenic response. Indeed, further testing with animal
models and purification of the active component(s) will be
necessary to provide the information required to determine the
Figure 5. Mechanism of action of poxvirus therapeutics. Illustration indicates the general replication cycle of VACV. The previously shown
targets of known antipoxvirus compounds, cidofovir and ST-246, are shown, as well as the presumptive target of the S. purpurea extract.
doi:10.1371/journal.pone.0032610.g005
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infections. Extensive animal studies to further characterize the
safety profile and antipoxvirus activity associated with S. purpurea
will be conducted, but insurmountable challenges exist in
conducting human trials associated with VACV, MPXV and
VARV infections. Although human trials to measure overall safety
associated with administration of S. purpurea can be done,
antipoxvirus studies cannot be conducted. Similar challenges have
also been observed with studies associated with the recently
identified antipoxvirus drug, ST-246, however this drug has been
used for the treatment of VACV-vaccination related complications
in humans [32].
It has been suggested that having multiple antipoxvirus
therapeutics which work by distinctly different mechanisms would
be beneficial during a smallpox epidemic or emergence of novel
poxvirus pathogens [22]. Many of the initially developed anti-
poxvirus compounds, like CDV, were nucleoside analogues [30].
Alternately,ST-246 acts by preventing extracellular virus forma-
tion which is essential for dissemination of the virus (Fig. 5) [21]. In
this study, we were able to demonstrate that S. purpurea specifically
affected early viral transcription, the first antiviral agent to be
characterized that targets poxviruses at this point in the replication
cycle (Fig. 5). Although solely based on in vitro studies, our work
supports the potential of S. purpurea as an additional treatment for
poxvirus infections, either individually or in combination with
other known antivirals.
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